Xilio Therapeutics, Inc. $XLO Shares Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC lifted its stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 252.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 225,994 shares of the company’s stock after buying an additional 161,832 shares during the period. Xilio Therapeutics makes up 0.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 24th biggest position. Stonepine Capital Management LLC owned 3.43% of Xilio Therapeutics worth $2,165,023 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of XLO. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Xilio Therapeutics by 61.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock worth $4,720,000 after acquiring an additional 2,805,869 shares during the period. Frazier Life Sciences Management L.P. bought a new position in shares of Xilio Therapeutics during the fourth quarter worth $3,787,000. Empery Asset Management LP purchased a new position in Xilio Therapeutics during the 4th quarter worth $757,000. Ghisallo Capital Management LLC acquired a new position in Xilio Therapeutics in the 4th quarter worth approximately $713,000. Finally, Renaissance Technologies LLC grew its stake in Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares in the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Trading Down 0.1%

Xilio Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $9.00. The company’s stock had a trading volume of 3,639 shares, compared to its average volume of 38,536. Xilio Therapeutics, Inc. has a 1 year low of $6.47 and a 1 year high of $12.74. The stock’s fifty day moving average is $9.09 and its two-hundred day moving average is $8.42. The firm has a market capitalization of $59.22 million, a PE ratio of -5.49 and a beta of -0.14.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.26. The company had revenue of $18.69 million for the quarter, compared to the consensus estimate of $12.72 million. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on XLO shares. Weiss Ratings downgraded Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.